Flu Remedies Help Combat E. coli Bacteria
News Aug 27, 2015
Trillions of bacteria populate the human gut - which makes them more common than any other cells in our body. The composition of this bacterial population is very variable and influenced by our diet. Diseases, but also antibiotic treatments can induce significant shifts in this equilibrium. If entire bacterial groups suddenly multiply heavily, critical situations occur. They damage the intestinal tissue and cause inflammations. How such shifts are triggered largely remained a mystery.
A carbohydrate causes E. coli to multiply
In their normal state, E. coli are harmless and only make up around 0.1 percent of the intestinal flora. If present in large amounts, however, they can cause diarrhea or a serious intestinal inflammation. The Zurich study reveals that an overproduction of E. coli can be attributed to the availability of the carbohydrate sialic acid, which is found in large amounts in the proteins of the intestinal mucosa. To actually be able to utilize the sialic acid, the bacteria enlist the aid of the enzyme sialidase, which is released by other intestinal bacteria. "It's striking that E. coli doesn't produce this kind of enzyme itself," explains Thierry Hennet, a professor from the Institute of Physiology at the University of Zurich.
Hennet and his colleagues succeeded in demonstrating the complex chain of events involved in a severe inflammation triggered by E. coli: An injury to the intestinal mucosa initially causes the increased multiplication of a non-pathogenic bacteria, which emits sialidase. This increased enzyme production releases sialic acid, which facilitates an overproduction of E. coliand can thus cause intestinal inflammation.
Sialidase inhibitors combat intestinal inflammations
The researchers also discovered that the intake of a sialidase inhibitor prevents the excessive formation of E. coli and was thus able to alleviate the disease symptoms. Interestingly, such sialidase inhibitors were already developed against the influenza virus. "Derivatives of known flu agents such as Tamiflu and Relenza could therefore also be used for inflammatory intestinal diseases, which opens up new therapeutic possibilities," says Hennet.
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Vaccine to One Hemorrhagic Virus Could Protect Against OthersNews
Scientists report that antibodies made in response to a vaccine against one hemorrhagic fever virus—Junin—can successfully disarm one of its cousins, Machupo, for which there’s currently no vaccine.READ MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018